BACKGROUND: More than 50% of American adolescents and adults report having used illicit drugs in their lifetime. We examined the association of lifetime opiate and cocaine use with reduced kidney function, albuminuria and rapid kidney function decline among urban-dwelling adults. METHODS: Our prospective cohort included 2,286 Healthy Aging in Neighborhoods of Diversity across the Life Span study participants who were community-dwelling adults residing in Baltimore, MD. The predictive variables were lifetime opiate and cocaine use, defined as use of opiates or crack/cocaine ≥5 times. Outcomes included prevalent reduced estimated glomerular filtration rate (eGFR; <60 ml/min/1.73 m2 by Chronic Kidney Disease (CKD)-Epidemiology Collaboration), albuminuria (albumin-to-creatinine ratio >30 mg/g, n = 1,652) and rapid kidney function decline (>3 ml/min/1.73 m2 per year over a median of 4.7 years, n = 1,660). RESULTS: Participants' mean age was 48 years, 15% reported opiate use, and 22% reported cocaine use. A total of 115 (5.0%) participants had reduced eGFR, 190 (11.5%) had albuminuria and 230 (13.8%) experienced rapid decline in kidney function. In adjusted logistic regression analyses, both substances were associated with greater odds of reduced eGFR (OR 2.71, 95% CI 1.50-4.89 for opiates; OR 1.40, 95% CI 0.87-2.24 for cocaine). Both substances were associated with greater odds of albuminuria (OR 1.20, 95% CI 0.83-1.73 for opiates; OR 1.80, 95% CI 1.29-2.51 for cocaine). Neither substance was associated with the rapid decline of kidney function. CONCLUSIONS: Lifetime opiate and cocaine use was associated with prevalent reduced eGFR and albuminuria, yet not with rapid kidney function decline. The use of opiate and cocaine may be an important risk factor for CKD in urban populations.
BACKGROUND: More than 50% of American adolescents and adults report having used illicit drugs in their lifetime. We examined the association of lifetime opiate and cocaine use with reduced kidney function, albuminuria and rapid kidney function decline among urban-dwelling adults. METHODS: Our prospective cohort included 2,286 Healthy Aging in Neighborhoods of Diversity across the Life Span study participants who were community-dwelling adults residing in Baltimore, MD. The predictive variables were lifetime opiate and cocaine use, defined as use of opiates or crack/cocaine ≥5 times. Outcomes included prevalent reduced estimated glomerular filtration rate (eGFR; <60 ml/min/1.73 m2 by Chronic Kidney Disease (CKD)-Epidemiology Collaboration), albuminuria (albumin-to-creatinine ratio >30 mg/g, n = 1,652) and rapid kidney function decline (>3 ml/min/1.73 m2 per year over a median of 4.7 years, n = 1,660). RESULTS:Participants' mean age was 48 years, 15% reported opiate use, and 22% reported cocaine use. A total of 115 (5.0%) participants had reduced eGFR, 190 (11.5%) had albuminuria and 230 (13.8%) experienced rapid decline in kidney function. In adjusted logistic regression analyses, both substances were associated with greater odds of reduced eGFR (OR 2.71, 95% CI 1.50-4.89 for opiates; OR 1.40, 95% CI 0.87-2.24 for cocaine). Both substances were associated with greater odds of albuminuria (OR 1.20, 95% CI 0.83-1.73 for opiates; OR 1.80, 95% CI 1.29-2.51 for cocaine). Neither substance was associated with the rapid decline of kidney function. CONCLUSIONS: Lifetime opiate and cocaine use was associated with prevalent reduced eGFR and albuminuria, yet not with rapid kidney function decline. The use of opiate and cocaine may be an important risk factor for CKD in urban populations.
Authors: N Di Paolo; V Fineschi; M Di Paolo; C V Wetly; G Garosi; M T Del Vecchio; G Bianciardi Journal: Clin Nephrol Date: 1997-05 Impact factor: 0.975
Authors: Sanjeev K Akkina; Ana C Ricardo; Amishi Patel; Arjun Das; Lydia A Bazzano; Carolyn Brecklin; Michael J Fischer; James P Lash Journal: Transl Res Date: 2012-06-23 Impact factor: 7.012
Authors: K C Norris; M Thornhill-Joynes; C Robinson; T Strickland; B L Alperson; S C Witana; H J Ward Journal: Am J Kidney Dis Date: 2001-09 Impact factor: 8.860
Authors: Jade S Hiramoto; Ronit Katz; Carmen A Peralta; Joachim H Ix; Linda Fried; Mary Cushman; David Siscovick; Walter Palmas; Mark Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2012-05-04 Impact factor: 8.860
Authors: Nabil Ghorayeb; Ricardo Stein; Daniel Jogaib Daher; Anderson Donelli da Silveira; Luiz Eduardo Fonteles Ritt; Daniel Fernando Pellegrino Dos Santos; Ana Paula Rennó Sierra; Artur Haddad Herdy; Claúdio Gil Soares de Araújo; Cléa Simone Sabino de Souza Colombo; Daniel Arkader Kopiler; Filipe Ferrari Ribeiro de Lacerda; José Kawazoe Lazzoli; Luciana Diniz Nagem Janot de Matos; Marcelo Bichels Leitão; Ricardo Contesini Francisco; Rodrigo Otávio Bougleux Alô; Sérgio Timerman; Tales de Carvalho; Thiago Ghorayeb Garcia Journal: Arq Bras Cardiol Date: 2019-03 Impact factor: 2.000
Authors: Ida V Stalund; Heidi Grønseth; Finn P Reinholt; Einar Svarstad; Hans-Peter Marti; Sabine Leh Journal: Clin J Am Soc Nephrol Date: 2022-03-16 Impact factor: 8.237
Authors: Kanaan Mansoor; Murad Kheetan; Saba Shahnawaz; Anna P Shapiro; Eva Patton-Tackett; Larry Dial; Gary Rankin; Prasanna Santhanam; Antonios H Tzamaloukas; Tibor Nadasdy; Joseph I Shapiro; Zeid J Khitan Journal: BMC Nephrol Date: 2017-12-29 Impact factor: 2.388
Authors: Daria Golosova; Oleg Palygin; Ruslan Bohovyk; Christine A Klemens; Vladislav Levchenko; Denisha R Spires; Elena Isaeva; Ashraf El-Meanawy; Alexander Staruschenko Journal: Life Sci Alliance Date: 2020-10-12